Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., and Endo Pharmaceuticals, have received U.S. FDA acceptance of the IND filing for a novel molecule targeting prostate cancer, which is anticipated to enter clinical trials in late 2013. The multi-target oncology collaboration entered four years ago, is focused on developing differentiated therapies that address the unmet needs of cancer patients worldwide. To date the collaboration has delivered on multiple discov...